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D iastolic function is a catch-all term referring to several different physiological processes that allow the left ventricle (LV) to fill with sufficient blood for the body's current needs at a low enough pressure to prevent pulmonary congestion. Diastole ( Table 1) actually begins in systole, as energy stored in titin within the myocyte and as torsion in the interstitial fibers of the myocardium. As systole ends, an abrupt untwisting occurs, which lowers pressure in the LV until the mitral valve (MV) opens, and blood flows along a negative pressure gradient (suction) toward the apex until the pressure equilibrates between the left atrium (LA) and the LV, resulting in diastasis until the final component of ventricular filling occurs with atrial contraction.
Derangement of any of these components may produce the pathophysiological entity of diastolic dysfunction ( Table 1) , a leading cause of the important and growing clinical syndrome of heart failure with preserved ejection fraction (HFpEF), which now accounts for $50% of all heart failure cases (1) .
Herein we present a comprehensive review of the echocardiographic early to late diastolic transmitral flow velocity (E/A) ratio and the E to early diastolic mitral annular tissue velocity (E/e 0 ) ratio, placing each of these tests in clinical context for the practicing clinician. We discuss: 1) the physiological basis for the E/A and E/e 0 ratios; 2) the role of these parameters in diagnosing diastolic dysfunction; 3) prognostic implications of abnormalities in E/A and E/e 0 ; 4) special scenarios of the E/A and E/e 0 ratios that are useful when evaluating diastolic function clinically; and 5) the usefulness of these indexes in guiding therapeutic decision making. (2) . Because these measurements are impractical for daily clinical practice, attention has been directed toward noninvasive methods, filling pattern is associated with an adverse prognosis in a variety of disease states (3, 13, 14) .
In neither of these situations is the physics A stepwise approach using E/A and E/e 0 to diagnose diastolic dysfunction. Proper assessment is dependent on an accurate acquisition of transmitral flow and tissue Doppler imaging. A LAVI of >28 ml/m 2 (as opposed to a cutoff of >34 ml/m 2 ) is used in the algorithm presented to indicate an increased LA size, because obesity is a risk factor for diastolic dysfunction; thus, LAVI can underestimate LA enlargement in these individuals (due to indexing to body size). *Although grading of diastolic dysfunction is not possible in these cases, the LVFP can still be estimated using surrogate markers, such as the estimated pulmonary artery systolic pressure or the end-diastolic pulmonary regurgitation gradient (as long as pulmonary arterial hypertension is not present). In older patients with normal sinus rhythm, systolic blunting of the pulmonary vein flow can be a sign of increased LA pressure. **It is not always possible to assign a diastolic dysfunction grade. In cases where equivocal data exists (e.g., an E/A ratio >0.8, reduced e' velocity, indeterminate range E/e', and normal LAVI), one can simply state that, "diastolic dysfunction is most likely present," without assigning a specific grade of diastolic dysfunction. In other cases, the e' velocity may be normal, but LA volume may be increased and an E/A ratio of >1, which can be seen in cases of increased cardiac output or athlete's heart. In these cases, one can simply state, "diastolic function is most likely normal." A ¼ late 
SPECIAL CLINICAL SCENARIOS
Although E/A and E/e 0 ratios can be very helpful clinically in diagnosing heart failure, predicting the (22, 26, 28, 29, 44) . Its usefulness rests largely on the "preload independence" of e 0 velocity, as measured in a recumbent position. Although e 0 typically shows less variation with preload alterations than E in pathological conditions, in normal subjects this is often not the case, with E/e 0 showing an almost flat response to variable LVEDP (27) . As noted previously, E/e 0 showed poor correlation with direct LA pressure measurements in patients with hypertrophic cardiomyopathy (28) .
Despite challenges in the interpretation of E/A and
E/e 0 ratio, specific patterns of these indexes can be quite helpful clinically, because they provide important diagnostic clues. Figure 3 displays some of these special scenarios in which specific E/A patterns and/ or E/e 0 ratio cutoffs can be used to guide diagnosis and management, and others where caution must be observed. In the case of atrial fibrillation, beat-to-beat variability and the absence of A waves make the wall such that the lateral e 0 velocity is now similar to or lower than septal e 0 velocity (annulus reversus because the lateral e 0 is normally higher than the septal e 0 ) (52).
The mitral inflow pattern can also help to determine the subtype of pulmonary hypertension (pulmonary arterial vs. pulmonary venous hypertension).
In patients with significantly elevated pulmonary artery systolic pressure (e.g., >50 mm Hg), an E/A ratio <1 is indicative of pulmonary arterial hypertension because the LA is underfilled (due to pulmonary vascular disease obstructing blood flow through the lungs), and extrinsic compression of the LV by the right ventricle, resulting in decreased LV compliance.
In these patients, lateral e 0 velocity is typically normal, but septal e 0 velocity is often reduced because the septal mitral annulus is also influenced by an abnormal right ventricle in the setting of pulmonary arterial hypertension. In patients with pulmonary venous hypertension, the lateral e 0 velocity is typically reduced, lateral E/e 0 is increased, and the E/A ratio should be >1 (53, 54) .
THERAPEUTIC DECISION MAKING
Echocardiography can be a powerful tool for the diagnosis of diastolic dysfunction and increased LV 
Ivabradine had no effect on exercise capacity or LV filling pressure. *p#0.05 for within-group differences. †p # 0.05 for between-group differences. dysfunction and/or HFpEF ( Table 2) Failure) trials, which examined patients with early phase HFpEF, treatment with spironolactone improved diastolic parameters but did not result in improved exercise capacity, a finding that supported the notion that in HFpEF, exercise intolerance is due to both cardiac and skeletal muscle dysfunction (58, 59) . In the TOPCAT trial (Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), which studied patients with more overt HFpEF (i.e., elevated B-type natriuretic peptide or history of heart failure hospitalization), a prespecified echocardiographic substudy showed that spironolactone reduced the E/A ratio, which was associated with reduced cardiovascular death and heart failure hospitalizations (60) . Table 2 show the usefulness of the E/A and E/e 0 ratios to vary by trial. PARAMOUNT (Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion) showed that in HFpEF, neprilysin inhibition reduced LA volume, but had no effect on the E/A or E/e 0 ratios (61). The SWEDIC study (Swedish Dopplerechocardiographic study) showed a signal that echocardiographic improvement in LV relaxation (E/A) could be dependent on heart rate control (62) . In 2 relatively small trials of ivabradine in HFpEF, the baseline E/A ratio proved to be quite informative; in earlier stages of HFpEF (denoted by lower E/A ratio), Kosmala et al. (63) found that ivabradine improved exercise capacity, whereas in later stage HFpEF (denoted by higher E/A ratio), Pal et al. (64) found no benefit with ivabradine. Although clear evidence is lacking, these findings suggest that heart rate reduction may be helpful only in the early stages of diastolic dysfunction and concomitant HFpEF when the E/A ratio is <1 (63, 64) . 
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